Another updated INDIGO analysis also reported that vorasidenib had a significantly lower rate of on-treatment seizures per person-year (18.2 vs. 51.2%, p = 0.0263) [61], suggesting that either tumor growth in the placebo arm led to higher seizure rates and/or that IDH inhibition actually has some antiseizure properties, as originally predicted based on preclinical work [62]. Here, IDH2 is linked to neoplasm.